Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies

被引:9
作者
De Aquino, Joao P. [1 ,2 ,3 ]
Bahji, Anees [4 ]
Gomez, Oscar [5 ]
Sofuoglu, Mehmet [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, 300 George St, New Haven, CT 06511 USA
[2] VA Connecticut Healthcare Syst, 950 Campbell Ave,151D, West Haven, CT 06516 USA
[3] Conneticut Mental Hlth Ctr, Clin Neurosci Res Unit CNRU, 34 Pk St,3rd Floor, New Haven, CT 06519 USA
[4] Univ Calgary, Cumming Sch Med, Dept Psychiat, 2500 Univ Dr NW, Calgary, AB, Canada
[5] Pontificia Univ Javeriana, Fac Med, Dept Psychiat, 7th St, Bogota 4002, Colombia
关键词
Delta-9-tetrahydrocannabinol (THC); Opioid use disorder; Opioid addiction; Methadone; Buprenorphine; NALOXONE-PRECIPITATED WITHDRAWAL; SEARCH STRATEGIES; ORAL DRONABINOL; USE DISORDER; METHADONE; ABSTINENCE; RECEPTORS; SYMPTOMS; IMPACT; LOFEXIDINE;
D O I
10.1016/j.drugalcdep.2022.109702
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: While six U.S. states have already officially authorized cannabinoids to substitute opioids and treat opioid use disorder, the therapeutic benefits of cannabinoids remain unclear, especially when weighted against their adverse effects.Methods: We conducted a systematic review of studies examining the association between opioid withdrawal and cannabis use or delta-9-tetrahydrocannabinol (THC) administration. We searched multiple databases from inception to July 30, 2022, and assessed study quality.Results: Eleven studies were identified, with a total of 5330 participants, of whom 64 % were male. Nine observational studies examined the association between cannabis use and opioid withdrawal. Two randomized, placebo-controlled clinical trials (RCTs) investigated the withdrawal-alleviating effects of dronabinol, a synthetic form of THC. Four observational studies found an association between cannabis use and the alleviation of opioid withdrawal; one reported exacerbation of opioid withdrawal symptoms; and four reported no association. RCTs reported that THC alleviated opioid withdrawal, albeit with dose-dependent increases in measures of abuse li-ability, dysphoria, and tachycardia. There was high heterogeneity in measurements of opioid withdrawal and the type and dose of opioid at baseline.Conclusions: Although there is preliminary evidence that cannabis and its main psychoactive constituent, THC, may alleviate opioid withdrawal, these effects are likely to have a narrow therapeutic window. Further, the potential of cannabinoids to alleviate opioid withdrawal is determined by complex interactions between patient characteristics and pharmacological factors. Collectively, these findings have clinical, methodological, and mechanistic implications for treating opioid withdrawal during cannabinoid use, and for efforts to alleviate opioid withdrawal using non-opioid therapeutics.
引用
收藏
页数:12
相关论文
共 77 条
[1]   Product Review: Covidence (Systematic Review Software) [J].
Babineau, Jessica .
JOURNAL OF THE CANADIAN HEALTH LIBRARIES ASSOCIATION, 2014, 35 (02) :68-71
[2]   Does Cannabis Use Influence Opioid Outcomes and Quality of Life Among Buprenorphine Maintained Patients? A Cross-sectional, Comparative Study [J].
Bagra, Igam ;
Krishnan, Vijay ;
Rao, Ravindra ;
Agrawal, Alok .
JOURNAL OF ADDICTION MEDICINE, 2018, 12 (04) :315-320
[3]   The impact of naturalistic cannabis use on self-reported opioid withdrawal [J].
Bergeria, Cecilia L. ;
Huhn, Andrew S. ;
Dunn, Kelly E. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 113
[4]   INHIBITION OF NALOXONE-INDUCED WITHDRAWAL IN MORPHINE-DEPENDENT MICE BY "L-TRANS-DELTA9-TETRAHYDROCANNABINOL [J].
BHARGAVA, HN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1976, 36 (01) :259-262
[5]  
BHARGAVA HN, 1976, PSYCHOPHARMACOLOGY, V49, P267, DOI 10.1007/BF00426828
[6]   The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone [J].
Bisaga, Adam ;
Sullivan, Maria A. ;
Glass, Andrew ;
Mishlen, Kaitlyn ;
Pavlicova, Martina ;
Haney, Margaret ;
Raby, Wilfrid N. ;
Levin, Frances R. ;
Carpenter, Kenneth M. ;
Mariani, John J. ;
Nunes, Edward V. .
DRUG AND ALCOHOL DEPENDENCE, 2015, 154 :38-45
[7]  
Calhoun SR, 1998, J PSYCHOACTIVE DRUGS, V30, P187
[8]   The Achilles Heel of Medical Cannabis Research-Inadequate Blinding of Placebo-Controlled Trials [J].
Casarett, David .
JAMA INTERNAL MEDICINE, 2018, 178 (01) :9-10
[9]   Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ9-tetrahydrocannabinol [J].
Cichewicz, DL ;
Welch, SP .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :812-817
[10]   Withdrawal symptoms predict prescription opioid dependence in chronic pain patients [J].
Coloma-Carmona, Ainhoa ;
Carballo, Jose L. ;
Rodriguez-Marin, Jesus ;
Perez-Carbonell, Ana .
DRUG AND ALCOHOL DEPENDENCE, 2019, 195 :27-32